{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:18:42Z","timestamp":1780078722495,"version":"3.54.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573445"],"award-info":[{"award-number":["81573445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7182115"],"award-info":[{"award-number":["7182115"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study","award":["BZ0150"],"award-info":[{"award-number":["BZ0150"]}]},{"name":"CAMS Innovation Fund for Medical Science","award":["2017-I2M-3-011"],"award-info":[{"award-number":["2017-I2M-3-011"]}]},{"name":"CAMS Innovation Fund for Medical Science","award":["2017-I2M-3-010"],"award-info":[{"award-number":["2017-I2M-3-010"]}]},{"name":"The Drug Innovation Major Project of China","award":["2018ZX09711001-003-001"],"award-info":[{"award-number":["2018ZX09711001-003-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1062-x","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T07:03:23Z","timestamp":1549263803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms"],"prefix":"10.1186","volume":"38","author":[{"given":"Min","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaona","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"1062_CR1","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","volume":"115","author":"NH Thoennissen","year":"2010","unstructured":"Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115:2882\u201390.","journal-title":"Blood"},{"key":"1062_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673\u201383.","journal-title":"Nat Rev Cancer"},{"key":"1062_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ajh.21183","volume":"83","author":"A Tefferi","year":"2008","unstructured":"Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008;83:491\u20137.","journal-title":"Am J Hematol"},{"key":"1062_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161\u201370.","journal-title":"N Engl J Med"},{"key":"1062_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1179\/102453309X12473408860226","volume":"14","author":"AL Basquiera","year":"2009","unstructured":"Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, Sackmann F, et al. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology. 2009;14:323\u201330.","journal-title":"Hematology"},{"key":"1062_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273\u201387.","journal-title":"Immunol Rev"},{"key":"1062_CR7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128\u201338.","journal-title":"Leukemia"},{"key":"1062_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"1062_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.semcdb.2014.03.023","volume":"28","author":"M Amoyel","year":"2014","unstructured":"Amoyel M, Anderson AM, Bach EA. JAK\/STAT pathway dysregulation in tumors: a Drosophila perspective. Semin Cell Dev Biol. 2014;28:96\u2013103.","journal-title":"Semin Cell Dev Biol"},{"key":"1062_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","volume":"75","author":"GL Plosker","year":"2015","unstructured":"Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75:297\u2013308.","journal-title":"Drugs"},{"key":"1062_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17:78.","journal-title":"Nat Rev Drug Discov"},{"key":"1062_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1875397300801010020","volume":"1","author":"C Harbert","year":"2008","unstructured":"Harbert C, Marshall J, Soh S, Steger K. Development of a HTRF kinase assay for determination of Syk activity. Curr Chem Genomics. 2008;1:20\u20136.","journal-title":"Curr Chem Genomics"},{"key":"1062_CR13","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.1021\/acs.jmedchem.7b01135","volume":"60","author":"T Siu","year":"2017","unstructured":"Siu T, Brubaker J, Fuller P, Torres L, Zeng H, Close J, et al. The discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1 H-pyrazole-4-carboxamide, a highly ligand efficient and efficacious Janus kinase 1 selective inhibitor with favorable pharmacokinetic properties. J Med Chem. 2017;60:9676\u201390.","journal-title":"J Med Chem"},{"key":"1062_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1021\/acsmedchemlett.7b00154","volume":"8","author":"AS Newton","year":"2017","unstructured":"Newton AS, Deiana L, Puleo DE, Cisneros JA, Cutrona KJ, Schlessinger J, et al. JAK2 JH2 fluorescence polarization assay and crystal structures for complexes with three small molecules. ACS Med Chem Lett. 2017;8:614\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"1062_CR15","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","volume":"60","author":"A Thorarensen","year":"2017","unstructured":"Thorarensen A, Dowty ME, Banker ME, Juba B, Jussif J, Lin T, et al. Design of a Janus Kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop \u22122-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J Med Chem. 2017;60:1971\u201393.","journal-title":"J Med Chem"},{"key":"1062_CR16","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","volume":"115","author":"P Koppikar","year":"2010","unstructured":"Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010;115:2919\u201327.","journal-title":"Blood"},{"key":"1062_CR17","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/leu.2011.148","volume":"25","author":"S Hart","year":"2011","unstructured":"Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011;25:1751\u20139.","journal-title":"Leukemia"},{"key":"1062_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.09.024","volume":"439","author":"D Martino De","year":"2018","unstructured":"De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett. 2018;439:56\u201365.","journal-title":"Cancer Lett"},{"key":"1062_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.apsb.2016.06.005","volume":"7","author":"G Lv","year":"2017","unstructured":"Lv G, Sun D, Zhang J, Xie X, Wu X, Fang W, et al. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharm Sin B. 2017;7:52\u20138.","journal-title":"Acta Pharm Sin B"},{"key":"1062_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657\u201367.","journal-title":"N Engl J Med"},{"key":"1062_CR21","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1038\/bcj.2011.43","volume":"1","author":"S Hart","year":"2011","unstructured":"Hart S, Goh KC, Novotny-Diermayr V, Tan YC, Madan B, Amalini C, et al. Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011;1:e44.","journal-title":"Blood Cancer J"},{"key":"1062_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","volume":"28","author":"SC Meyer","year":"2015","unstructured":"Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell. 2015;28:15\u201328.","journal-title":"Cancer Cell"},{"key":"1062_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/leu.2011.261","volume":"26","author":"G Wernig","year":"2012","unstructured":"Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26:720\u20137.","journal-title":"Leukemia"},{"key":"1062_CR24","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1073\/pnas.0601462103","volume":"103","author":"CH Jamieson","year":"2006","unstructured":"Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103:6224\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1062_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/leu.2011.292","volume":"26","author":"AV Purandare","year":"2012","unstructured":"Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012;26:280\u20138.","journal-title":"Leukemia"},{"key":"1062_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coi.2016.10.001","volume":"43","author":"K Hirahara","year":"2016","unstructured":"Hirahara K, Schwartz D, Gadina M, Kanno Y, O'Shea JJ. Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol. 2016;43:89\u201397.","journal-title":"Curr Opin Immunol"},{"key":"1062_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"key":"1062_CR28","first-page":"945","volume":"8","author":"R Buettner","year":"2002","unstructured":"Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945\u201354.","journal-title":"Clin Cancer Res"},{"key":"1062_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00441-016-2364-3","volume":"363","author":"H Niknejad","year":"2016","unstructured":"Niknejad H, Yazdanpanah G, Ahmadiani A. Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. Cell Tissue Res. 2016;363:599\u2013608.","journal-title":"Cell Tissue Res"},{"key":"1062_CR30","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/blood-2006-08-039735","volume":"109","author":"MB Hookham","year":"2007","unstructured":"Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109:4924\u20139.","journal-title":"Blood"},{"key":"1062_CR31","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","volume":"124","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124:3529\u201337.","journal-title":"Blood"},{"key":"1062_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","volume":"414","author":"JP Hu","year":"2018","unstructured":"Hu JP, Hu WX. Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett. 2018;414:214\u201321.","journal-title":"Cancer Lett"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1062-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T19:31:37Z","timestamp":1580758297000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1062-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were approved by the Experimental Animal Welfare and Ethics Committee of the Institute of Materia Medica, Chinese Academy of medical Sciences (No. 001004). And a written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All contributing authors agree to the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"49"}}